Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, to participate in Bio-Europe Spring digital event on 23-27 March
Emergence Therapeutics, a new European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers, has launched its new company website.
Emergence Therapeutics’ science is being harnessed to develop best- or first-in-class antibody drug conjugates (ADCs) for the treatment of solid tumors. Its lead product is ETx-01, an ADC against Nectin-4. The company’s aim is to target difficult to treat tumors with high efficacy, lower risk of side effects and the ability to avoid resistance.
Dr. Jack Elands, Chief Executive Officer of Emergence Therapeutics, said: “Launching our new company website gives us the opportunity to share more information about Emergence Therapeutics and our research progress with all of our key stakeholders. Together with our unique science, strong management team, important collaborators and investors we are exceptionally well positioned as a new company to develop truly novel ADC immuno-therapeutics for hard to treat cancers. I look forward to updating everyone on our scientific progress through 2020 and beyond.”
Dr. Jack Elands will be attending the Bio-Europe Spring 2020 digital event being held from 23-27 March 2020. Due to the ongoing COVID-19 situation, the meeting will take place as a fully digital event and will provide attendees with digital opportunities to engage with global life science partners. If you would like to meet Dr. Elands, please contact him via firstname.lastname@example.org.
About Emergence Therapeutics
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugate (ADC) immuno-therapeutics to treat high-need cancers. Its lead program, ETx-1, uses innovative linker technology and the proprietary payload amanitin to target Nectin-4 – an important and validated target for a broad range of cancers. Emergence is developing ETx-01 to target cancers with Nectin-4 expression and 17p deletions, areas of high unmet need. Beyond ETx-01 Emergence is actively exploring opportunities to develop further best- or first-in-class ADCs driven by therapeutic need.
Emergence has entered into a licensing and collaboration agreement with SATT Sud-Est (the regional tech transfer office for Aix-Marseille Université, CNRS and Inserm) through which the Company has been granted exclusive rights to a set of anti-Nectin-4 antibodies developed by Dr. Marc Lopez at the Cancer Research Center of Marseille, France. SATT Sud-Est is also providing financial support to the Emergence program.
ETx-01 is being developed under a licensing and collaboration agreement with Heidelberg Pharma Research GmbH, a subsidiary of Heidelberg Pharma AG. Through this agreement Emergence has access to Heidelberg Pharma’s amanitin-based payloads and corresponding linkers (proprietary ATAC Technology). Heidelberg Pharma Research is also a founding investor in Emergence.
Emergence is led by a strong management team and is supported by a network of world-leading scientists who have contributed significantly to the field of immuno-oncology. Emergence is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information, please visit: www.emergencetx.com.